Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
HOME > ARCHIVE
ARCHIVE
- Halaven Receives Positive Opinion from CHMP
February 7, 2011
- Nasivin M Spray Approved as Class 1 OTC Drug
February 7, 2011
- Astellas, Kaketsuken Tie Up to Market Encevac
February 7, 2011
- Gilenya Receives Positive Opinion from CHMP: Novartis
February 7, 2011
- JSMI to Propose Tax Break for All OTC Drugs
February 7, 2011
- AnGes MG to Raise ¥300 Mil. from Shionogi to Develop NF-κB Oligo
February 7, 2011
- GRU to Target Online Sales of OTC Drugs, Basic Dispensing Fees
February 7, 2011
- Shionogi to Recall Class 3 OTC Drugs
February 7, 2011
- MTPC Terminates Joint Development of Roflumilast with Nycomed
February 7, 2011
- Present Industry's Opinions to Office of Medical Innovation: Mr Kawakami
February 7, 2011
- Sunovion Aims at Rapid Market Entry for Latuda by Replacing Existing Products
February 7, 2011
- Hayashibara Applies for Business Revitalization ADR
February 7, 2011
- FJPWA Calls For Resumption of Ryukaikon
February 7, 2011
- Takeda, MSD Call For Precautions on Similar Drug Names
February 7, 2011
- Meiji Seika, Fresenius Kabi Ally to Develop Anticancer Generics Business in Japan
February 7, 2011
- NBI's Mirapex Recommended for Approval
February 7, 2011
- Mochida Aims at Sales of ¥10 Bil. with Generics
February 7, 2011
- Making Whole of Japan Large Pharmaceutical Company: Prof. Nakamura
February 7, 2011
- Nichi-Iko to Raise ¥20 Bil. through Public Stock Offerings
February 7, 2011
- Pfizer Aims for Approval of 7 Products Each Year: President Umeda
February 7, 2011
ページ
Japan’s pharmaceutical industry is undergoing a structural shift in its workforce, with the role of sales reps shrinking while production…
In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…